Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
hydroxypropyl beta cyclodextrin (VAR 200) / ZyVersa
NCT06489340: P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease	Recruiting	2	8	US	2HPβCD, 2-hydroxypropyl-β-cyclodextrin	ZyVersa Therapeutics, Inc.	Diabetic Kidney Disease	03/26	03/26
IC 100 / ZyVersa
No trials found
IC 200 / ZyVersa
No trials found
IC 300 / ZyVersa
No trials found
VAR 400 / ZyVersa
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
hydroxypropyl beta cyclodextrin (VAR 200) / ZyVersa
NCT06489340: P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease	Recruiting	2	8	US	2HPβCD, 2-hydroxypropyl-β-cyclodextrin	ZyVersa Therapeutics, Inc.	Diabetic Kidney Disease	03/26	03/26
IC 100 / ZyVersa
No trials found
IC 200 / ZyVersa
No trials found
IC 300 / ZyVersa
No trials found
VAR 400 / ZyVersa
No trials found